PP-592 前立腺癌多発骨転移に対する塩化ストロンチウム(89Sr)の使用経験(前立腺腫瘍/放射線治療5・その他,一般演題ポスター,第97回日本泌尿器科学会総会)

Background/Objectives Hidradenitis suppurativa has been associated with a number of pathologies, including various endocrine and autoimmune disorders. Although signs of hyperandrogenism are common in hidradenitis suppurativa, few formal studies have assessed the relationship between hidradenitis suppurativa and polycystic ovarian syndrome. Therefore, we performed a systematic review and meta‐analysis to assess the association between hidradenitis suppurativa and polycystic ovarian syndrome. Methods We performed a systematic review and meta‐analysis according to PRISMA guidelines. Odds ratio was used as the effect size, with random‐effects meta‐analysis. Results We identified five case‐control studies for inclusion. From pooled data, we found a significantly higher proportion of polycystic ovarian syndrome in hidradenitis suppurativa cases compared with controls ( OR 2.64; 95% CI 1.69–4.11; P < 0.00001). There was significant heterogeneity noted ( I 2 = 88%, P < 0.00001). Limitations included that studies reviewed were observational by design which are susceptible to bias, and lack of randomisation. Conclusions In summary, pooled analysis of existing case‐control studies supports a significant association between hidradenitis suppurativa and polycystic ovarian syndrome. Our results imply that hidradenitis suppurativa patients with signs of hyperandrogenism may benefit from screening for polycystic ovarian syndrome, and may potentially benefit from anti‐androgen therapy.